Introduction
The Human Proteome Organization (HUPO), formed in 2001, has launched several major initiatives. These are focused on the plasma proteome, the liver proteome, the brain proteome, protein standards/bioinformatics, and certain technologies, including large-scale antibody production. Overall, HUPO aims to accelerate the development of the field of proteomics and to stimulate and organize international collaborations in research and education [1] .
The HUPO Plasma Proteome Project (PPP) has three major long-term scientific goals: (1) a comprehensive analysis of the protein constituents of human plasma and serum; (2) the identification of biological sources of variation within individuals over time, leading to validated biomarkers. These sources are physiological (age, sex, menstrual cycle, exercise), pathological (various diseases, special cohorts) and pharmacological (common medications); and (3) the determination of the extent of variation across populations and across individuals within populations (genetic, nutritional and other factors).
Blood samples have the virtues of being highly accessible sources of human specimens. There are extensive specimen archives (banks), some with extensive clinical annotation. The circulating proteins are a dynamic reflection of organ functions in health and disease.
Planning for the Plasma Proteome Project
In the initial planning meetings in Bethesda, Maryland, 29 April 2002, and in Ann Arbor, Michigan, 5-6 September 2002, highly interdisciplinary groups of experts from academe, government and industry proposed that there be a pilot phase to address the following ten scientific issues: (1) sensitivity of various techniques to deal with the huge dynamic range of concentrations of proteins and peptides in the circulation; (2) many technical aspects of specimen collection, handling, storage, and thawing, aiming for standardization; (3) methods of depleting or prefractionating the most abundant several proteins; (4) comparisons of the advantages and limitations or interferences associated with serum vs plasma, and alternative anticoagulation methods for plasma (EDTA, heparin, citrate); (5) enumeration and categorization of proteins visualized and identi-fied, with special attention to post-translational modifications and tissue of origin; (6) separation of intact proteins vs separation of peptides from digested proteins; (7) use of gel-based vs liquid phase multi-dimensional separation methods; (8) parameters for high-throughput links with mass spectrometry; (9) comparisons of MALDI vs direct MS (SELDI) methods; and (10) assessment and advancement of specific labeling chemistries.
The aims for the pilot phase are presented in Table 1 and Figure 1 . [6] at Pacific Northwest National Laboratory used microcapillary liquid-phase chromatography, digestion to peptides, and ion-trap mass spectrometry on samples in which immunoglobulins were depleted using binding proteins (proteins A/G) and reported 490 distinct proteins. Then Pieper et al. [7] fractionated serum proteins by immunoaffinity chromatography to remove eight highly abundant proteins (albumin, haptoglobin, transferrin, transthyretin, alpha-1 antitrypsin, alpha-1 acid glycoprotein, hemo- pexin, alpha-2 macroglobulin), followed by sequential anionexchange and size exclusion chromatography, before 2-DE. They resolved about 3700 protein spots and identified 1800 by MS, which were recognized as 325 distinct proteins after sequence homology and similarity searches to eliminate redundancies [7] . The potential importance of inhibition of protease activity was demonstrated by Marshall et al. [8] .
At the First HUPO World Congress on Proteomics in Versailles in November 2002, we presented plans for the PPP, elicited interest from many laboratories interested in participating, and established an organizational structure with active Technical Committees ( Table 2) . (2) BD Diagnostics sets of four reference specimens for each of three ethnic groups: Caucasian-American, African-American and Asian-American. Each pool consisted of one unit of blood each from one male and one postmenopausal female healthy, fasting donor, collected in a standard donor set-up after informed consent, and immediately pooled, then divided into four equal volumes in bags with appropriate concentrations of K-EDTA, lithium heparin, or sodium citrate for plasma and without clot activator for serum. This procedure required 2 h at room temperature. Each pool was then aliquoted into numerous 250 mL portions in vials which were then frozen and stored at 2707C. Aliquots were tested for HIV, HBV and HCV. We supply sets of 46250 mL aliquots for each of the four plasma/serum specimens. These vials plus the NIBSC ampoules were shipped frozen on dry ice via courier in early May 2003.
(3) The Chinese Academy of Medical Sciences sets of four reference specimens. This pool was prepared, after review by the CAMS Ethics Committee and informed consent by donors, according to the BD protocol in #2, including tests for viral infections. We supply sets of 46250 mL aliquots for each of the four plasma/serum specimens. Following various approvals and time for controlling the severe acute respiratory syndrome (SARS) outbreak, these specimens were shipped in September 2003. 
Commitment of participating laboratories

Guidance from Technical Committees and the Bethesda Workshop
There has been extensive communication among the chairs and some members of the various committees (see Table 2 ). In May 2003, in preparation for the July 16-17 Bethesda Workshop, all participating laboratories were sent draft formats and guidance for submission of information about experimental protocols and results from the various studies of specimens. These formats were prepared by a PPP working group led by Richard Simpson of Ludwig Institute, Melbourne. Testing the limits of the methods, we proposed that results be expressed in accordance with the output of each type of technology platform, with emphasis on confidence of identification of proteins. Further, we proposed that investigators estimate the relative abundance of the proteins from spot density or absorbance peak or other methods (see Section 3.5).
The formats were reviewed in detail by investigators from 35 of the laboratories and members of the technical committees and sponsors at the Bethesda Workshop. Investigators were given the option of submitting data in Excel to the Bioinformatics Database Core, where the results would be entered; of inviting technical assistance from the Core, in order to deploy XML for submission directly into the data repository; or to use XML themselves, with which some laboratories were already familiar. The Protein Experimental Data Reporting tool (PEDRo) is being prepared for linking with the XML submission. Labs were requested to identify the protein database and search engine they utilized; following discussions in the Bioinformatics Committee and the full meeting, investigators were strongly encouraged to use the International Protein Index (IPI) search engine.
Participating laboratories and technology vendors presented updates on several platforms: Agilent -immunoaffinity column to remove the six most abundant proteins: albumin, immunoglobulin (Ig) G, IgA, haptoglobin, transferrin, and alpha-1 anti-trypsin; GenWay -chicken IgY antihuman antibodies for depletion or detection of specific proteins; BD Diagnostics -development of new collection tubes with protease inhibitors; Gradipore -fractionation cartridges; Invitrogen -zoom electrophoresis/ microscale solution IEF/MALDI; and Tecan -free flow electrophoresis. Early results with HUPO reference specimens were presented by Nakamura (Yamaguchi University, Japan) with 2-D gels and by Petricoin (FDA, USA) with SELDI direct mass spectrometry.
Database development
The HUPO PPP has based its primary data repository at the European Bioinformatics Institute (EBI), which has the lead for Protein Standards (PSI) and Bioinformatics for all HUPO initiatives under the direction of Henning Hermjakob. The aim is to have a consolidated inventory of plasma/serum proteins, linked with organ-derived proteomes of other HUPO initiatives and with SWISS-PROT and other databases maintained at EBI. The specimen tracking, descriptions of experimental protocols, and related study-specific database are at 
Administration and dissemination of findings
The HUPO PPP has its administrative hub at the University of Michigan. Funding has been developed both from corporate sponsors and from a trans-National Institutes of Health (NIH) consortium of several NIH institutes. These funds will support extensive bioinformatics services and the database, distribution of reference specimens, workshops and associated travel, administrative services, and some support for collaborative experimental and data mining protocols. Liaison with the other HUPO initiatives is assured. Intellectual property plans have been clarified: the PPP is committed to public Figure 2 . Quantitative determination of 37 coded proteins by immunoassay from set of four specimens from same donor pool (EDTA-, heparin-, and citrate-anticoagulated plasma plus serum), with reference ranges domain release of its results, with ample opportunities for academic, government, or corporate laboratories to undertake proprietary development of biomarkers and targets/agents with the methodologies evaluated in the pilot phase of the PPP. We are planning an intensive workshop, perhaps modeled on the Drosophila Genome Jamboree, for cross-technology platform, cross-reference specimen, cross-laboratory analyses of the extensive findings of this project.
During the completion of the pilot phase during [2003] [2004] , initial planning will be undertaken for large-scale population cohort studies in collaboration with investigators responsible for many such existing and planned disease-oriented cohorts. A special issue of Proteomics dedicated to findings from the HUPO PPP is planned for late 2004, and other publications and electronic media have invited papers from this project.
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